# A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT00910754** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 33 (actual)

## Conditions studied

- Prostate Neoplasms

## Interventions

- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00910754
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-11
- **Final completion:** 2012-05
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2013-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910754, "A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00910754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*